Biomarkers of predicting response to neoadjuvant chemoradiotherapy in esophageal cancer.
- Author:
Jian-hua FU
1
Author Information
1. Department of Thoracic Oncology, Cancer Center, Sun Yat-sen University, State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China. fujh@sysucc.org.cn.
- Publication Type:Editorial
- MeSH:
Biomarkers, Tumor;
Chemoradiotherapy;
Esophageal Neoplasms;
drug therapy;
radiotherapy;
surgery;
Humans;
Neoadjuvant Therapy;
methods;
Treatment Outcome
- From:
Chinese Journal of Gastrointestinal Surgery
2013;16(9):805-810
- CountryChina
- Language:Chinese
-
Abstract:
The prognosis of patients with locally advanced esophageal cancer treated by surgery alone is poor. The neoadjuvant chemoradiotherapy is considered to improve the long-term survival of patients with locally advanced esophageal cancer. The combination of neoadjuvant chemoradiotherapy and surgery has been recommended to be the standard treatment for the locally advanced esophageal cancer in China even in Europe and America countries. However, available evidence suggests that only those who had histopathologic response seemed to benefit the most from neoadjuvant chemotherapy while non-responders even had rather worse outcome compared to patients with surgery alone. Therefore, predictive markers of response to neoadjuvant chemoradiotherapy in locally advanced esophageal cancer are highly significant and needed. These markers would allow a tailored treatment to guide non-responders to alternative preoperative therapies and ultimately avoid ineffective, costly and seriously cytotoxic treatments. Results of most studies on biomarkers for predicting response to neoadjuvant chemoradiotherapy in esophageal cancer are promising. The potential utilization of biomarkers in clinical practice is urgently expected and needed, which plays an important role in guiding and improving the individualization of multimodality therapy in locally advanced esophageal cancer.
